NCT01462318 - An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | Biotech Hunter

Enrollment

133

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Midazolam

5 mg

OTHER

Caffeine

200 mg

DRUG

S-warfarin

10 mg

OTHER

Vitamin K

10 mg

DRUG

Omeprazole

40 mg

DRUG

Dextromethorphan

30 mg

BIOLOGICAL

BIIB019 (Daclizumab)

150 mg in 1 ml PFS

Trial Locations (19)

1134

Research Site, Budapest

2500

Research Site, Esztergom

4031

Research Site, Debrecen

8200

Research Site, Veszprém

20057

Research Site, Washington D.C.

37064

Research Site, Franklin

40513

Research Site, Lexington

41501

Research Site, Teplice

45417

Research Site, Dayton

48334

Research Site, Farmington Hills

53203

Research Site, Pardubice

58633

Research Site, Jihlava

60010

Research Site, Lake Barrington

65691

Research Site, Brno

70852

Research Site, Ostrava

80112

Research Site, Centennial

Unknown

Research Site, Székesfehérvár

Research Site, Katowice

31-501

Research Site, Krakow